Eravacycline for treatment of complicated intra-abdominal infections: the fire is not ignited!

Honoré, Patrick M.; Spapen, Herbert D.

doi:10.21037/atm.2017.08.15

Cited by 3 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is important to anticipate a few challenges with the clinical use of ERV in the real‐world setting. The unfavorable response of E. faecalis , which was observed in the IGNITE1 trial, is concerning, particularly for a drug with relatively good gram‐positive bacterial activity . Unfortunately, there are limited data to support the use of ERV to date in urgent threats such as Acinetobacter spp .…”

Section: Place In Therapymentioning

confidence: 99%

“…The unfavorable response of E. faecalis, which was observed in the IGNITE1 trial, is concerning, particularly for a drug with relatively good gram-positive bacterial activity. 73,88 Unfortunately, there are limited data to support the use of ERV to date in urgent threats such as Acinetobacter spp. On the other hand, ERV exhibited clinical cure with at least 80% of patients with infections due to P. aeruginosa even with noted poor in vitro activity against this organism.…”

Section: Place In Therapymentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Eravacycline: A Novel Fluorocycline

et al. 2020

View full text Add to dashboard Cite

Eravacycline (ERV), formerly known as TP‐434, is a novel tetracycline (TET) antibiotic that exhibits in vitro activity against various gram‐positive, gram‐negative aerobic and anaerobic pathogens, including those exhibiting TET‐specific acquired resistance mechanisms. Similar to other TETs, it inhibits protein synthesis through binding to the 30S ribosomal subunit. Eravacycline was approved by the United States Food and Drug Administration (FDA) in August 2018 for the treatment of complicated intraabdominal infections (cIAIs) in adults following the Investigating Gram‐Negative Infections Treated with Eravacycline (IGNITE)1 and IGNITE4 phase III trials. In these two, double‐blind, multicenter clinical trials, ERV was proven noninferior in terms of clinical response in comparison to ertapenem and meropenem, respectively. Eravacycline was well tolerated with nausea, vomiting, and infusion site reactions being the most commonly reported adverse reactions. Clinicians now have ERV as a novel therapeutic option for the treatment of adults with intraabdominal infections, allergies to β‐lactam agents, Clostridioides difficile‐associated diarrhea, or if tolerability to other agents is a concern.

show abstract

Section: Place In Therapymentioning

confidence: 99%

Section: Place In Therapymentioning

confidence: 99%